The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Post-osimertinib landscape for NSCLC
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, comments on the complexity of the post-osimertinib space in non-small cell lung cancer (NSCLC), noting the resurgence of other drugs and the development of new targeted therapies, including antibody-drug conjugates (ADCs) such as patritumab deruxtecan and bispecific antibodies, as well as ongoing studies targeting C797S resistance. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
